Oncology Therapeutics Network
Recent technological upgrades help explain a lower-than-usual 17% growth rate during second quarter, Bristol's Winningham explains. An e-commerce initiative undertaken in 1999 has "been able to help physician's offices carry lower relative inventories of oncology products." Similarly, the installation of 750 dispensing machines in oncologist's offices in the U.S. has reduced inventory levels. The new services, coupled with a lack of new oncology product launches in the first half of 2000, explain the drop-off from 36% growth in 1999, he said
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth